The nisotirostide obesity trial is an early test of a different obesity-research strategy: pairing <a href="https://glp1place.com/tools/compound/glp-1/”>GLP-1 signaling with a separate pathway involved in appetite and metabolism. In a phase 1 study published October 3, 2026, researchers evaluated nisotirostide, also known as LY3457263, a selective neuropeptide Y2 receptor agonist. The study included 65 participants and examined the investigational compound alone and alongside dulaglutide, a GLP-1 receptor agonist.
The early results were mixed. In the reported monotherapy comparison, 1 mg of nisotirostide was associated with a mean body-weight reduction of 0.75 kg versus placebo, but the difference was not statistically significant. When nisotirostide was added to dulaglutide, the study reported up to 2.58 kg of additional weight reduction compared with dulaglutide alone. Nausea and vomiting were the most common reported adverse events and were described as mild to moderate. The primary publication is available through PubMed.
These findings are a proof-of-concept signal, not evidence of a ready-to-use obesity treatment. The trial was small and early in development. It cannot establish durable weight loss, long-term safety, cardiovascular benefit, a preferred regimen, or whether the combination will perform well in broader populations. Still, it introduces NPY2 signaling as a possible complement to GLP-1 research.
What is nisotirostide?
Nisotirostide is an investigational molecule that selectively activates the neuropeptide Y2 receptor, usually shortened to NPY2R. Its development code is LY3457263. NPY receptors are part of a signaling system involved in appetite, food intake, energy balance, and glucose regulation.
NPY2R is relevant because it is part of a gut-brain network that helps the body respond to food. One naturally occurring signal linked to this system is peptide YY, or PYY. The intestine releases PYY after eating, and it is associated with satiety, or the feeling of fullness that can reduce further food intake.
An NPY2 receptor agonist is not simply a stronger GLP-1 medicine. GLP-1 receptor agonists can affect insulin secretion, glucagon signaling, stomach emptying, appetite, and food reward. NPY2 signaling is a separate biological pathway. The research question is whether acting on both pathways could produce complementary effects.
That distinction matters. Nisotirostide is not another GLP-1 analog, a dual GLP-1/GIP agonist, or a triple GLP-1/GIP/glucagon agonist. It represents an effort to expand obesity and metabolic research beyond the incretin pathways that currently receive much of the attention.
How was the nisotirostide obesity trial designed?
The published report included preclinical experiments and a first-in-human phase 1 clinical study. The preclinical work evaluated body weight, food intake, body composition, glucose, and insulin-related measures. The human study focused on pharmacokinetics, safety, tolerability, and early clinical activity.
Pharmacokinetics describes how the body absorbs, distributes, and clears a compound. In an early trial, these data help researchers understand exposure over time and plan later studies. They do not establish that a compound is effective for routine care.
The human component enrolled 65 participants. Researchers assessed nisotirostide as monotherapy and as an add-on to dulaglutide. This allowed the study to examine two early questions:
- Could nisotirostide show a measurable weight-related or metabolic signal on its own?
- Could adding nisotirostide to a GLP-1 receptor agonist produce more weight reduction than the GLP-1 drug alone?
Because it was phase 1 research, the study was not designed to provide a definitive test of obesity treatment. Phase 1 trials usually emphasize exposure, tolerability, and early pharmacology. Larger phase 2 and phase 3 trials are needed to determine whether an early signal is reproducible, clinically meaningful, and acceptably safe over longer periods.
The paper reported a pharmacokinetic profile that supported once-weekly development. That finding may help guide future research, but it is not a treatment schedule or administration recommendation. Nisotirostide remains investigational, and a protocol detail from an early study is not personal medical guidance.
What weight-change results did the study report?
The main result was the contrast between monotherapy and combination treatment. In the monotherapy analysis, the reported 1 mg nisotirostide comparison showed mean body weight 0.75 kg lower than placebo. The difference was not statistically significant. Put simply, this small study did not provide reliable evidence that nisotirostide alone produced meaningful weight loss at the tested dose and stage of development.
The combination finding drew more attention. When nisotirostide was added to dulaglutide, the study reported up to 2.58 kg of additional weight reduction compared with dulaglutide alone. The publication described that result as significant in the tested comparison. It should still be considered exploratory because it came from a small phase 1 study. The published report provides the study design and reported outcomes.
Several limits matter when interpreting this result. The total study population was only 65 people. A phase 1 trial is generally not powered to estimate weight-loss differences precisely across many groups. The finding also does not establish the percentage of baseline body weight lost, whether the effect persisted, or how the combination would perform over many months.
It also cannot be directly compared with headline weight-loss percentages from later-stage obesity trials. Those studies often include more participants, run longer, involve different populations, and use different endpoints. An absolute difference in kilograms from a short early study is not equivalent to a percentage weight-change result from a long phase 3 program.
| Study question | Reported finding | What it means |
|---|---|---|
| Nisotirostide alone | 0.75 kg lower mean body weight versus placebo at 1 mg | The difference was not statistically significant and does not establish monotherapy efficacy. |
| Nisotirostide plus dulaglutide | Up to 2.58 kg greater reduction versus dulaglutide alone | This is an early combination signal that requires confirmation. |
| Pharmacokinetics | Profile supported once-weekly development | This informs future research rather than treatment use. |
| Tolerability | Nausea and vomiting were most common | Gastrointestinal effects need evaluation in larger and longer trials. |
Why study an NPY2 receptor agonist with GLP-1 therapy?
The rationale is pathway complementarity. A GLP-1 receptor agonist can reduce appetite and improve glucose regulation, but treatment response and tolerability vary. Researchers are exploring whether a second pathway can add benefit without relying only on greater stimulation of the first pathway.
NPY2 signaling may influence appetite through neural and intestinal signals that differ from GLP-1 signaling. In the preclinical work described in the paper, nisotirostide was associated with changes in food intake, body weight, glucose, and insulin-related biology. The authors also described weight-independent glucose improvements in preclinical models. These observations provided a biological rationale for testing the compound with a GLP-1 receptor agonist.
Combination therapy is already an important theme in obesity research. Some programs combine GLP-1 activity with GIP, glucagon, or amylin-related pathways. GLP1Place has covered the separate evidence for retatrutide’s triple-receptor approach and the different metabolic findings from the Pep19 obesity trial. Nisotirostide is distinct because it is a non-incretin receptor strategy intended to complement, rather than replace, GLP-1 signaling.
Future work may show whether NPY2 activation affects body composition, glucose control, appetite, or gastrointestinal tolerability differently from additional incretin stimulation. At this stage, these possibilities remain hypotheses. The phase 1 report does not prove that the mechanism will be more effective or safer than existing approaches.
What safety and tolerability findings were reported?
Gastrointestinal adverse events were the most common reported findings. Nausea and vomiting were described as dose-dependent and mild to moderate in severity. This pattern is relevant for a compound acting in appetite and gut-brain signaling, but a small early trial cannot define a full safety profile.
For obesity medicines, effectiveness and tolerability are closely connected. A compound can show biological activity but still be difficult to continue if adverse effects limit exposure. Combination approaches may create the same challenge through two pathways. Later research will need to determine whether any added weight-related benefit comes with an acceptable treatment burden.
The available study does not establish the frequency or long-term importance of every possible adverse event. It also does not include enough exposure to assess uncommon risks. Small phase 1 trials can identify some short-term tolerability patterns, but they cannot rule out rare, delayed, or population-specific safety concerns.
Future reports will need to describe adverse events by treatment group, duration, severity, and discontinuation status. They will also need to assess whether gastrointestinal symptoms change with continued exposure and whether the combination affects laboratory or clinical measures relevant to broader metabolic health.
What limits the interpretation of this early study?
The first limitation is sample size. Sixty-five participants can help characterize early pharmacology and identify some common tolerability patterns. That number cannot provide a precise estimate of effectiveness in a broad obesity population.
The second limitation is duration. Weight management is a long-term condition. Studies lasting many months or years are needed to assess whether weight reduction is maintained, whether metabolic changes persist, and whether adverse events accumulate. This phase 1 report cannot answer those questions.
The third limitation is the endpoint. The reported combination result of up to 2.58 kg is an absolute weight-change comparison, not a percentage reduction from baseline. It therefore should not be placed beside percentage results from longer trials as if the measures were interchangeable.
The fourth limitation concerns interpretation of sponsored development research. The paper lists Eli Lilly employees and stockholders among its authors. That does not invalidate the findings. Company-sponsored studies are common in drug development. It does mean that transparent methods, careful peer review, and independent replication are especially important.
Finally, the study did not establish superiority over an approved or investigational obesity medicine. It tested a new biological strategy in an early clinical setting. The measured conclusion is that nisotirostide showed pharmacologic and preliminary clinical activity sufficient to justify further research, not that it has an established treatment role.
How nisotirostide fits into next-generation obesity research
The obesity-drug pipeline is moving beyond single-pathway medicines. <a href="https://glp1place.com/tools/compound/semaglutide/”>Semaglutide activates the GLP-1 receptor. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon activity. Amylin-based candidates pursue another satiety-related route. Nisotirostide adds NPY2R to this wider research map.
The important difference is that NPY2R is not an incretin receptor. It may offer a way to influence appetite and glucose metabolism through a separate signaling network. That could matter if later studies show an additive effect without a proportional increase in nausea, vomiting, or other burdens.
More receptor activity does not automatically make a medicine better. Any added pathway must translate into durable weight change, acceptable tolerability, a reasonable benefit-risk profile, and meaningful health outcomes. Each mechanism can also introduce effects that require careful monitoring.
For now, the early data raises a focused scientific question: can selective NPY2 activation improve outcomes when paired with a GLP-1 receptor agonist, or will the combination mainly increase gastrointestinal effects? Controlled phase 2 trials will be needed to begin answering that question.
What later trials should measure
Next-stage studies should be larger, randomized, and long enough to measure clinically meaningful outcomes. A useful program would clearly separate nisotirostide alone, the GLP-1 drug alone, the combination, and placebo where scientifically appropriate.
Key outcomes should include mean percentage weight change, responder thresholds, and treatment-completion rates. Body-composition data would help show whether changes involve fat mass, lean mass, or both. Metabolic measures could include glycated hemoglobin, fasting glucose, insulin-related markers, blood pressure, lipids, and liver-related measures.
Tolerability reporting will be just as important as effectiveness reporting. Later studies should provide detailed information on nausea, vomiting, appetite suppression, discontinuation, and nutritional adequacy. Longer follow-up is needed to assess durability. Independent confirmation beyond the original sponsor’s development network would also strengthen confidence in the findings.
Researchers will also need to define the intended population. The program could eventually be studied in obesity, type 2 diabetes, incomplete response to GLP-1 therapy, or a narrower metabolic subgroup. This phase 1 signal cannot determine which population, if any, will benefit most.
Regulatory status of nisotirostide
Nisotirostide is investigational. The October 3, 2026 publication is not approval by the U.S. Food and Drug Administration or another regulator. It does not establish a clinical indication, a recommended dose, a route for personal use, a combination plan, or a self-administration procedure.
It is useful to distinguish a published phase 1 report from a completed phase 2 program, a regulatory filing, and an approved therapy. These are different milestones with different evidence standards. A published paper can advance scientific understanding while still leaving major questions about effectiveness and safety unresolved.
Why the nisotirostide obesity trial matters
The significance of nisotirostide will depend on whether later trials address a meaningful limitation of current obesity treatment. A new mechanism has value only if it improves the balance among weight reduction, glucose control, tolerability, durability, convenience, and health outcomes.
The dulaglutide add-on finding gives the program a clear development rationale. If reproduced, NPY2 activation could become part of a future research strategy for people who do not have a sufficient response to GLP-1-based therapy. It could also offer a model for combining gut-derived satiety biology with established incretin signaling.
But the signal could become smaller or disappear in a larger sample. Early studies can produce wide estimates because they include relatively few participants and may explore multiple doses or groups. An encouraging phase 1 result must be tested more rigorously before it can support clinical conclusions.
For now, the defensible conclusion is measured: nisotirostide has entered human development with a biologically distinct mechanism, a pharmacokinetic profile supporting once-weekly research development, and an early combination signal with dulaglutide. The program is worth watching as research, but it is not yet evidence that NPY2 therapy will change obesity care.
Key points from the phase 1 report
- Nisotirostide, or LY3457263, is a selective NPY2 receptor agonist.
- The first reported human study included 65 participants.
- The reported 1 mg monotherapy comparison showed 0.75 kg of mean weight reduction versus placebo without statistical significance.
- Adding nisotirostide to dulaglutide produced up to 2.58 kg of additional weight reduction versus dulaglutide alone.
- Nausea and vomiting were the most common reported adverse events and were described as mild to moderate.
- The findings support further research but do not establish long-term effectiveness or safety.
- Nisotirostide remains investigational and is not an approved obesity treatment.
Frequently asked questions about nisotirostide
What is nisotirostide?
Nisotirostide, also called LY3457263, is an investigational selective NPY2 receptor agonist being studied for type 2 diabetes and obesity. It is designed to activate a pathway involved in appetite and metabolic regulation.
What did the nisotirostide obesity trial test?
The phase 1 study evaluated nisotirostide in 65 participants. It examined pharmacokinetics, safety, and early weight-related findings when nisotirostide was used alone and when it was added to dulaglutide.
Did nisotirostide produce significant weight loss on its own?
In the reported monotherapy comparison, 1 mg of nisotirostide reduced mean body weight by 0.75 kg versus placebo, but the difference was not statistically significant. That result is too early and too limited to establish a weight-loss effect.
Did nisotirostide work better with dulaglutide?
The study reported up to 2.58 kg of additional weight reduction when nisotirostide was added to dulaglutide compared with dulaglutide alone. This was an exploratory phase 1 finding that needs confirmation in larger and longer randomized trials.
What side effects were reported with nisotirostide?
Gastrointestinal adverse events, including nausea and vomiting, were the most common reported events. They were described as dose-dependent and mild to moderate in the early study.
Is nisotirostide approved for obesity or diabetes?
No. Nisotirostide remains investigational. The phase 1 evidence does not establish approval, routine effectiveness, long-term safety, or a recommended treatment regimen.